Stock IGC IGC PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases IGC Pharma, Inc.

Equities

IGC

US45408X3089

Market Closed - Nyse
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
0.487 USD -2.60% Intraday chart for IGC Pharma, Inc. -0.49% +73.87%
May. 28 IGC Pharma Begins Patient Enrollment for Mid-Stage Trial of IGC-AD1 to Treat Alzheimer's-Related Agitation MT
May. 28 IGC Pharma, Inc. Announces Patient Enrollment At Neurostudies in Phase 2 Trial Investigating IGC-AD1 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
IGC Pharma Announces Patient Enrollment at Neurostudies, Inc. in Phase 2 Trial Investigating IGC-AD1
AQ
IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1
BU
IGC Pharma to Attend BIO International Convention 2024
BU
6.7 Million Americans Live With Alzheimer’s – IGC Pharma Believes They Deserve Treatment Options Without Black Box Warnings
AQ
IGC PHARMA : Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
PU
IGC-AD1'S Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two
AQ
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
BU
IGC Pharma Adds Advisor in Artificial Intelligence
BU
IGC Pharma : Announces Positive Interim Results for IGC-AD1 in - Form 8-K
PU
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
BU
IGC Pharma : Material Agreement - Form 8-K
PU
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation
AQ
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
BU
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
BU
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
BU
Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model
BU
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target
BU
IGC Pharma Reports Third Quarter Fiscal 2024 Results
BU
IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model
BU
IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IGC Stock
  4. News IGC Pharma, Inc.
  5. Press Releases